LEVIT Levetiracetam 500mg Film-Coated Tablet 1's
RXDRUG-DR-XY46913-1pc
Discreet Packaging
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
FDA-registered Products
FDA-licensed Pharmacies
Features
Brand
Levit
Full Details
Dosage Strength
500 mg
Drug Ingredients
- Levetiracetam
Drug Packaging
Film-Coated Tablet 1's
Generic Name
Levetiracetam
Dosage Form
Film-Coated Tablet
Registration Number
DR-XY46913
Drug Classification
Prescription Drug (RX)
Description
Indications/Uses
Levetiracetam is used as adjunctive therapy in the treatment of partial seizures with or without secondary generalization.
Dosage/Direction for Use
The initial dose of Levetiracetam is 1 g on the first day of treatment in two divided doses. Thereafter the daily dose may be increased in increments of 1 g every 2 to 4 weeks until effective antiepileptic control is achieved, up to a maximum dose of 3 g daily or as prescribed by the physician. As with other antiepileptics, withdrawal of Levetiracetam therapy or transition to or from another type of antiepileptic therapy should be made gradually to avoid precipitating an increase in the frequency of seizures.
Administration
May be taken with or without food.
Special Precautions
Levetiracetam should be used with caution in renal impairment; dosage reduction in patients with reduced renal function or those undergoing haemodialysis. Renal function should also be assessed in patients with severe hepatic impairment, and the dose adjusted accordingly.
Adverse Reactions
The most commonly reported adverse effects associated with Levetiracetam are somnolence, weakness, and dizziness. Anorexia, diarrhea, dyspepsia, nausea, ataxia, headache, amnesia, depression, emotional liability, insomnia, aggression, nervousness, tremor, vertigo, diplopia and rash may occur less frequently.
Storage
Store at temperatures not exceeding 30°C.
Action
Pharmacology: Pharmacokinetics: Levetiracetam is readily absorbed from the gastrointestinal tract and peak plasma concentrations are usually achieved within 1.3 hours of oral administration and steady-state achieved after 2 days. Levetiracetam is not extensively metabolized; approximately 25% of the dose is metabolized by hydroxylation and the metabolites are inactive. About 95% of a dose is excreted as unchanged drug and metabolites in the urine. Plasma protein binding is minimal. The plasma elimination half-life has been reported to be about 7 hours.
MedsGo Class
Anticonvulsants
Please sign in so that we can notify you about a reply